Inivata
Natera Sues NeoGenomics for Patent Infringement
Natera alleges that NeoGenomics is infringing on two patents related to the Signatera minimal residual disease testing platform.
Natera Files Second Patent Infringement Suit Against NeoGenomics Subsidiary Inivata
The suit was filed the same day Natera received a new patent covering its patient-specific residual cancer testing and monitoring methods.
The firm has submitted data to the Centers for Medicare and Medicaid Services' MolDx program to pursue reimbursement.
Princess Margaret Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
Inivata's InVisionFirst-Lung and RaDaR assays will support studies of the use of liquid biopsies in early and minimal residual disease detection.
F-Star Therapeutics to Use Inivata's RaDaR Assay in Clinical Studies
F-star will use the ctDNA assay to identify potential early biomarkers of clinical efficacy and evaluate treatment response for late-stage solid tumors.